Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 915-920

  Church, L W Preston ^b   Le, Thong P ⁱ   Bryan, Joe P ⁱ   Gordon, Daniel M ^c   Edelman, Robert ⁱ   Fries, Louis ^d   Davis, Jonathan R ^e   Herrington, Deirdre A ^f   Clyde, David F ⁱ   Shmuklarsky, Moshe J ⁱ   Schneider, Imogene ⁱ   McGovern, Thomas W ^g   Chulay, Jeffrey D ^h   Ballou, W Ripley ⁱ   Hoffnian, Stephen L ^a  

^a NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d Nabi Biopharmaceuticals   (United States)

^e U S DEPARTMENT OF STATE   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g FITZSIMONS ARMY MEDICAL CENTER   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTHRALGIA; ARTICLE; BLEEDING; CHILL; CLINICAL FEATURE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; MOSQUITO; MYALGIA; NEUTROPENIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROVOCATION TEST; THROMBOCYTOPENIA;

EID: 16944362968     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513990     Document Type: Article

References (12)

1. Chulay JD, Schneider I, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986;35:66-8.
2. Ballou WR, Hoffman SL, Sherwood JA, et al. Safety and immunogenicity of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987; 1:1277-81.
3. Herrington DA, Clyde DF, Losonsky G, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987;328:257-9.
4. Herrington DA, Clyde DF, Murphy JR, et al. A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitemia for efficacy studies of sporozoite vaccines. Trop Geogr Med 1988;40: 124-7.
5. 3-TT and immunization with irradiated sporozoites. Bull World Health Organ 1990;68(suppl):33-7.
6. Rickman LS, Jones TR, Long GW, et al. Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg 1990;43:441-5.
7. Herrington D, Davis J, Nardin E, et al. Successful immunization of humans with malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991; 5:539-47.
8. Fries LF, Gordon DM, Schneider I, et al. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun 1992; 60:1834-9.
9. Egan JE, Hoffman SL, Haynes JD, et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993;49:166-73.
10. Edelman R, Hoffman SL, Davis JR, et al. Long-term persistence of sterile immunity in a volunteer immunized with x-irradiated Plasmodium falciparum sporozoites. J Infect Dis 1993; 168:1066-70.
11. Shmuklarsky MJ, Boudreau EF, Pang LW, et al. Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. Ann Intern Med 1994; 120:294-9.
12. Hoffman SL, Edelman R, Bryan JP, et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 1994; 51:603-12.